MA54231A - Composés de 2-formyl-3-hydroxyphényloxyméthyle capables de moduler l'hémoglobine - Google Patents

Composés de 2-formyl-3-hydroxyphényloxyméthyle capables de moduler l'hémoglobine

Info

Publication number
MA54231A
MA54231A MA054231A MA54231A MA54231A MA 54231 A MA54231 A MA 54231A MA 054231 A MA054231 A MA 054231A MA 54231 A MA54231 A MA 54231A MA 54231 A MA54231 A MA 54231A
Authority
MA
Morocco
Prior art keywords
hydroxyphenyloxymethyl
formyl
compounds capable
hemoglobin
modulating
Prior art date
Application number
MA054231A
Other languages
English (en)
Other versions
MA54231B1 (fr
Inventor
Zhe Li
Original Assignee
Global Blood Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Global Blood Therapeutics Inc filed Critical Global Blood Therapeutics Inc
Publication of MA54231A publication Critical patent/MA54231A/fr
Publication of MA54231B1 publication Critical patent/MA54231B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La présente invention concerne de manière générale des composés et des compositions pharmaceutiques appropriés en tant que modulateurs de l'hémoglobine, et des procédés pour leur utilisation dans le traitement de troubles à médiation par l'hémoglobine.
MA54231A 2018-11-19 2019-11-18 Composés de 2-formyl-3-hydroxyphényloxyméthyle capables de moduler l'hémoglobine MA54231B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862769196P 2018-11-19 2018-11-19
US201962821314P 2019-03-20 2019-03-20
US201962848773P 2019-05-16 2019-05-16
US201962883313P 2019-08-06 2019-08-06

Publications (2)

Publication Number Publication Date
MA54231A true MA54231A (fr) 2021-09-22
MA54231B1 MA54231B1 (fr) 2021-12-31

Family

ID=68848454

Family Applications (1)

Application Number Title Priority Date Filing Date
MA54231A MA54231B1 (fr) 2018-11-19 2019-11-18 Composés de 2-formyl-3-hydroxyphényloxyméthyle capables de moduler l'hémoglobine

Country Status (29)

Country Link
US (4) US10683285B2 (fr)
EP (2) EP3880654B1 (fr)
JP (1) JP7509772B2 (fr)
KR (1) KR102842589B1 (fr)
CN (1) CN113316568B (fr)
AU (1) AU2019383960B2 (fr)
BR (1) BR112021007044B1 (fr)
CA (1) CA3120380A1 (fr)
CO (1) CO2021007993A2 (fr)
CR (1) CR20210335A (fr)
CY (1) CY1125025T1 (fr)
DK (1) DK3880654T3 (fr)
ES (1) ES2908325T3 (fr)
HR (1) HRP20220295T1 (fr)
HU (1) HUE057323T2 (fr)
IL (1) IL283128B2 (fr)
LT (1) LT3880654T (fr)
MA (1) MA54231B1 (fr)
MD (1) MD3880654T2 (fr)
MX (1) MX2021005887A (fr)
PL (1) PL3880654T3 (fr)
PT (1) PT3880654T (fr)
RS (1) RS62970B1 (fr)
SA (1) SA521422031B1 (fr)
SG (1) SG11202104705RA (fr)
SI (1) SI3880654T1 (fr)
SM (1) SMT202200106T1 (fr)
TW (1) TWI841630B (fr)
WO (1) WO2020106642A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015021982B1 (pt) 2013-03-15 2022-12-13 Global Blood Therapeutics, Inc Compostos e seus usos para a modulação de hemoglobina
KR102280614B1 (ko) 2013-03-15 2021-07-21 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
AU2014237330A1 (en) 2013-03-15 2015-09-17 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
SI3102208T2 (sl) 2014-02-07 2024-10-30 Global Blood Therapeutics, Inc. Kristalinični polimorf proste baze 2-hidroksi-6-((2-(1-izopropil-1H-pirazol-5-IL)piridin-3-IL)metoksi)- benzaldehida
US11020382B2 (en) 2015-12-04 2021-06-01 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
EP3680241A1 (fr) 2017-03-20 2020-07-15 Forma Therapeutics, Inc. Compositions de pyrrolopyrrole en tant qu'activateurs de pyruvate kinase (pkr)
US10675274B2 (en) 2018-09-19 2020-06-09 Forma Therapeutics, Inc. Activating pyruvate kinase R
WO2020061255A1 (fr) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activation de la pyruvate kinase r
EP3860975B1 (fr) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulateurs de l'hémoglobine pour le traitement de la drépanocytose
JP7509772B2 (ja) * 2018-11-19 2024-07-02 グローバル ブラッド セラピューティクス インコーポレイテッド ヘモグロビンのモジュレーター
HUE072832T2 (hu) 2019-09-19 2025-12-28 Novo Nordisk Healthcare Ag Piruvát kináz R-t (PKR) aktiváló készítmények
CA3176429A1 (fr) * 2020-03-31 2021-10-07 Global Blood Therapeutics, Inc. Modulateurs de l'hemoglobine
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
JP2024520896A (ja) * 2021-05-14 2024-05-27 グローバル ブラッド セラピューティクス インコーポレイテッド ヘモグロビンのモジュレーターを作製する方法
TW202311254A (zh) * 2021-05-14 2023-03-16 美商全球血液治療公司 血紅素之調節劑之固態形式
WO2023003332A1 (fr) 2021-07-19 2023-01-26 주식회사 바이오앱 Vecteur d'expression de protéine de spicule recombinante de variant de la covid-19 d'origine végétale et protéine recombinante l'utilisant
IL312835A (en) * 2021-12-10 2024-07-01 Global Blood Therapeutics Inc Methods for administering a hemoglobin modulator
TW202515579A (zh) 2023-06-13 2025-04-16 美商全球血液治療公司 投予血紅素的調節劑之方法
WO2025262596A1 (fr) * 2024-06-20 2025-12-26 Pfizer Inc. Procédés de fabrication d'osivélotor

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
EP0022229B1 (fr) 1979-06-29 1982-12-08 The Wellcome Foundation Limited Ethers de phénol substitués, leur préparation, intermédiaires pour leur préparation, compositions pharmaceutiques les contenant et leur préparation
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
GR76950B (fr) 1980-12-18 1984-09-04 Wellcome Found
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
JPS63258463A (ja) 1987-04-14 1988-10-25 Kumiai Chem Ind Co Ltd ２−フエノキシピリミジン誘導体及び除草剤
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
EP0658559A1 (fr) 1993-12-14 1995-06-21 Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. Dérivés thiénothianine, procédé pour leur préparation et leur application comme inhibiteurs de 5-dipoxygenase et cyclooxygenase
HK1043106A1 (zh) 1998-12-14 2002-09-06 F. Hoffmann-La Roche Ag 苯基甘氨酸衍生物
CZ20013469A3 (cs) 1999-03-31 2002-04-17 Basf Aktiengesellschaft Diamidy pyridin-2,3-dikarboxylových kyselin
PL375532A1 (en) 2002-08-08 2005-11-28 Smithkline Beecham Corporation Benzimidazol-1-yl-thiophene compounds for the treatment of cancer
EP1567490B1 (fr) 2002-12-04 2011-10-05 Virginia Commonwealth University Agents anti-drepanocytaire
RU2337908C2 (ru) 2003-06-12 2008-11-10 Ново Нордиск А/С Пиридинилкарбаматы в качестве ингибиторов гормон-чувствительной липазы
US7847120B2 (en) 2004-04-22 2010-12-07 Virginia Commonwealth University Intellectual Property Foundation Compositions of allosteric hemoglobin modifiers and methods of making the same
NZ564759A (en) 2005-06-30 2011-08-26 Prosidion Ltd GPCR agonists
CN100562514C (zh) 2005-07-22 2009-11-25 中国科学院上海药物研究所 一类取代丙酰胺衍生物、其制备方法和用途
TW200835687A (en) 2006-11-30 2008-09-01 R Tech Ueno Ltd Thiazole derivatives and their use as VAP-1 inhibitor
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
EP2271341B1 (fr) 2008-05-08 2016-08-17 Nova Southeastern University Inhibiteurs specifiques des recepteurs du facteur de croissance de l'endothelium vasculaire
GB0811451D0 (en) 2008-06-20 2008-07-30 Syngenta Participations Ag Novel microbiocides
TW201033201A (en) 2009-02-19 2010-09-16 Hoffmann La Roche Isoxazole-isoxazole and isoxazole-isothiazole derivatives
DK3738434T3 (da) 2011-12-28 2023-12-04 Global Blood Therapeutics Inc Mellemprodukter til opnåelse af substituerede benzaldehydforbindelser og fremgangsmåder til anvendelse deraf ved øgning af vævsoxygenering
WO2013102145A1 (fr) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Composés d'aldéhydes hétéroaryles substitués et leurs procédés d'utilisation dans l'accroissement de l'oxygénation tissulaire
BR112015021982B1 (pt) * 2013-03-15 2022-12-13 Global Blood Therapeutics, Inc Compostos e seus usos para a modulação de hemoglobina
KR102280614B1 (ko) 2013-03-15 2021-07-21 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AU2014237361A1 (en) * 2013-03-15 2015-09-17 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US20140271591A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compositions and methods for the modulation of hemoglobin (s)
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20150057251A1 (en) 2013-08-26 2015-02-26 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2015031284A1 (fr) 2013-08-26 2015-03-05 Global Blood Therapeutics, Inc. Formulations comprenant des agents mouillants et des composés pour la modulation d'hémoglobine (s)
US20160207904A1 (en) 2013-08-27 2016-07-21 Global Blood Therapeutics, Inc. Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
US20150141465A1 (en) 2013-11-18 2015-05-21 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9248199B2 (en) 2014-01-29 2016-02-02 Global Blood Therapeutics, Inc. 1:1 adducts of sickle hemoglobin
SI3102208T2 (sl) 2014-02-07 2024-10-30 Global Blood Therapeutics, Inc. Kristalinični polimorf proste baze 2-hidroksi-6-((2-(1-izopropil-1H-pirazol-5-IL)piridin-3-IL)metoksi)- benzaldehida
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
US11020382B2 (en) 2015-12-04 2021-06-01 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
AR108435A1 (es) 2016-05-12 2018-08-22 Global Blood Therapeutics Inc Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
JP7509772B2 (ja) * 2018-11-19 2024-07-02 グローバル ブラッド セラピューティクス インコーポレイテッド ヘモグロビンのモジュレーター

Also Published As

Publication number Publication date
US20210047309A1 (en) 2021-02-18
ES2908325T3 (es) 2022-04-28
EP4046988A1 (fr) 2022-08-24
US20230159507A1 (en) 2023-05-25
DK3880654T3 (da) 2022-03-07
MD3880654T2 (ro) 2022-05-31
US11548880B2 (en) 2023-01-10
MA54231B1 (fr) 2021-12-31
IL283128B1 (en) 2024-11-01
CA3120380A1 (fr) 2020-05-28
KR102842589B1 (ko) 2025-08-04
EP3880654B1 (fr) 2021-12-29
TW202039460A (zh) 2020-11-01
IL283128B2 (en) 2025-03-01
CN113316568B (zh) 2024-11-08
SG11202104705RA (en) 2021-06-29
JP7509772B2 (ja) 2024-07-02
US20260103454A1 (en) 2026-04-16
LT3880654T (lt) 2022-02-25
MX2021005887A (es) 2021-09-14
HUE057323T2 (hu) 2022-04-28
PL3880654T3 (pl) 2022-04-25
US20200157085A1 (en) 2020-05-21
TWI841630B (zh) 2024-05-11
BR112021007044B1 (pt) 2022-04-19
PT3880654T (pt) 2022-04-08
BR112021007044A2 (pt) 2021-07-27
WO2020106642A1 (fr) 2020-05-28
EP3880654A1 (fr) 2021-09-22
AU2019383960B2 (en) 2024-10-10
JP2022509091A (ja) 2022-01-20
AU2019383960A1 (en) 2021-06-10
SA521422031B1 (ar) 2023-12-24
SMT202200106T1 (it) 2022-05-12
CO2021007993A2 (es) 2021-06-30
SI3880654T1 (sl) 2022-04-29
WO2020106642A8 (fr) 2020-12-30
IL283128A (en) 2021-06-30
KR20210093990A (ko) 2021-07-28
CR20210335A (es) 2021-09-14
RS62970B1 (sr) 2022-03-31
HRP20220295T1 (hr) 2022-05-13
CY1125025T1 (el) 2023-03-24
US10683285B2 (en) 2020-06-16
CN113316568A (zh) 2021-08-27

Similar Documents

Publication Publication Date Title
MA54231B1 (fr) Composés de 2-formyl-3-hydroxyphényloxyméthyle capables de moduler l'hémoglobine
MA57825B1 (fr) Tétrahydrofuranes substitués en tant que modulateurs de canaux sodiques
MA50240B1 (fr) Modulateurs de la protéine régulatrice de la conductance transmembranaire de la fibrose kystique et procédés d'utilisation
MA42397B1 (fr) 4-azaindoles substituées et leur utilisation comme modulatoeurs de la récepteur glun2b
MA40290A1 (fr) Agents immunorégulateurs
MA53861B1 (fr) Modulateurs de promédicaments de la voie de réponse intégrée au stress
MA64509B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA64121B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
WO2019035864A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles sanguins
MA50406B1 (fr) Inhibiteurs pyrazole de magl
MA43113A (fr) Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci
EA201891799A1 (ru) Замещенные 1,2,3-триазолы в качестве nr2b-селективных модуляторов nmda
MX2020007731A (es) Compuestos moduladores de receptor de estrogeno.
MA49947B1 (fr) Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
BR112019001923A2 (pt) moduladores de nmda de espiro-lactama e métodos de sua utilização
MA40768A (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
BR112022000855A2 (pt) Moduladores de nlrp3
MX2021015500A (es) Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b.
MA40769B1 (fr) Indoles mono ou di-substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MA39346A1 (fr) Hétérocycles substitués liés par fusion en tant que modulateurs gpr119 pour le traitement du diabète, de l'obésité, de la dyslipidémie et de troubles associés
MA39972A (fr) Composés et compositions d'induction de la chondrogenèse
CR20210580A (es) Amidas depirazol-piridina sustituidos y su uso como moduladores del receptor glun2b
BR112021014566A2 (pt) Moduladores de gpr35
WO2017177024A8 (fr) Méthodes de traitement de troubles oculaires
MA52482B1 (fr) Dérivés de spiropipéridine en tant que modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine